文献速递皮肤肿瘤

日光性角化病管理费用的地理差异

Variation in the Cost of Managing Actinic Keratosis.
PubMed 文献 · JAMA Dermatol · 2017-01-01

结果显示调整后最高与最低五分位费用比为1.72至1.80,高于Medicare十种常见病的1.33至1.69,提示AK管理存在价值改进空间。

要点

  • AK管理年费用存在地区内和地区间差异,调整后Q5:Q1比为1.72至1.80。
  • 该差异不能完全由年龄、性别、合并症等患者特征解释。
  • AK费用差异高于Medicare十种常见病,提示需改进管理价值。

核心结论

  • AK管理成本存在地区内和地区间差异,且不能完全由患者特征差异解释。
  • 与Medicare十种常见病相比,AK的Q5:Q1比值更高,提示管理价值有改进机会。

研究设计与样本

  • 回顾性队列研究,使用MarketScan医疗索赔数据库。

主要发现

  • 未调整的每患者年总费用Q5:Q1比为9.49至15.10,调整后为1.72至1.80。

关键数值与推荐

  • 费用按2014年美元进行通胀调整。
  • Q5:Q1比值为最高五分位平均费用与最低五分位平均费用的比值,调整因素包括年龄、性别、非黑色素瘤皮肤癌病史、美国地理区域和人口密度(大都市统计区)。
  • Medicare十种常见病的Q5:Q1比值为1.33(背/颈部关节退变)至1.69(慢性鼻窦炎),AK为1.72至1.80。

临床怎么用

  • 临床管理中应关注AK治疗费用的地区差异,评估高费用地区的管理策略。
  • 可针对费用差异探索减少浪费或回收超额支出的措施,以提高AK管理价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Actinic keratosis (AK), a skin growth induced by ultraviolet light exposure, requires chronic management because a small proportion can progress into squamous cell skin cancer. Spending for AK management was more than $1 billion in 2004. Investigating geographic variation in AK spending presents an opportunity to decrease waste or recoup excess spending. OBJECTIVE: To evaluate geographic variation in health care cost for management of AKs and the association with patient-related and health-related factors. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was performed using data from the MarketScan medical claims database of 488 324 continuously enrolled members with 2 or more claims for AK. Data from January 1, 2008, to December 31, 2012, was used. MAIN OUTCOMES AND MEASURES: Annual costs of care were calculated for outpatient visits, AK destruction, and medications for AKs, and the total of these components. Costs were adjusted for inflation to 2014 US dollars. To display cost variation, we calculated the ratio of mean cost in the highest quintile (Q5) relative to the mean in the lowest quintile (Q1), or the Q5:Q1 ratio; Q5:Q1 ratios were adjusted based on age, sex, history of nonmelanoma skin cancer, US geographic region, and population density (metropolitan statistical area). RESULTS: Overall, data from 488 324 continuously enrolled members (mean [SD] age, 53.1 [7.5] years; 243 662 women) with 2 or more claims for AK were included. Overall, patients had 1 085 985 claims related to AK, and dermatologists accounted for 71.0% of claims. The 2-year total cost was $111.5 million, with $52.4 million in 2011 and $59.1 million in 2012. The unadjusted Q5:Q1 ratios for total annual cost per patient ranged from 9.49 to 15.10. Adjusted ratios ranged from 1.72 to 1.80. CONCLUSIONS AND RELEVANCE: There is variation in AK management cost within and between regions. This is not fully explained by differences in patient characteristics such as age, sex, or comorbidities. The annual cost for 10 common conditions from Medicare had lower Q5:Q1 ratios that ranged from 1.33 (joint degeneration of back/neck) to 1.69 (chronic sinusitis) when compared with 1.72 to 1.80 for AKs. This suggests an opportunity to investigate and improve the value of health care delivery in the management of AKs.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Kirby JS, Gregory T, Liu G, et al. Variation in the Cost of Managing Actinic Keratosis. JAMA Dermatol. 2017. PMID: 28249074. doi:10.1001/jamadermatol.2016.4733

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。